A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients with Rheumatoid Arthritis Inadequately Responding to Biological Disease-modifying Antirheumatic Drugs

Anti-Fractalkine Antibody Suppresses Joint Destruction by Inhibiting Migration of Osteoclast Precursors to the Synovium in Experimental Arthritis

(2018) Kana Hoshino-Negishi et al.   Arthritis & Rheumatology

Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis

(2017) Yoshiya Tanaka et al.   Modern Rheumatology

Current concepts in the management of rheumatoid arthritis

(2016) Yoshiya Tanaka   KOREAN JOURNAL OF INTERNAL MEDICINE

Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges

(2015) Josef S. Smolen et al.   Nature Reviews Rheumatology

Fractalkine Promotes Human Monocyte Survival via a Reduction in Oxidative Stress

(2014) Gemma E. White et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Nr4a1-Dependent Ly6Clow Monocytes Monitor Endothelial Cells and Orchestrate Their Disposal

(2013) Leo M. Carlin et al.   CELL

Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis

(2012) Yoshiya Tanaka   CURRENT OPINION IN RHEUMATOLOGY

Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors

(2010) Jérôme Cros et al.   IMMUNITY